Maribavir (SHP620) Clinical Development Overview

Obi Umeh, MD, MS Global Development Lead, Shire




Maribavir Phase 2 Studies Data Presentation

	Description	Authors <u>Presenting Author</u>	Congress		20)16		2017				
Type of Presentation				1	2	3	4	1	2	3	4	
Oral Posters	Study 202: Primary efficacy and safety Study 203: Primary efficacy and safety	Papanicolaou G, Silveira F, Langston A, Pereira M, Avery R, Wijatyk A, Wu J, Boeckh M, Marty F, Villano S Maertens J, Cordonnier C, Jaksch P, Poire X, Wu J, Wijatyk A, <u>Saliba F</u> , Witzke O, Villano S	ID Week 2016				~					
Oral Presentation	Study 202: Primary efficacy and safety data, and pre- specified subgroup analyses by transplant type (SOT vs SCT)	<u>Papanicolaou G</u> , Silveira F, Langston A, Pereira M, Avery R, Wijatyk A, Wu J, Boeckh M, Marty F, Villano S	BMT Tandem 2017					~				
Oral Plenary Presentation	Study 202: Primary efficacy and safety data, and pre- specified subgroup analyses by transplant type (SOT vs SCT)	<u>M R. Pereira</u> , F P. Silveira,G Papanicolaou, A Langston, R Avery, A Wijatyk,J J. Wu, M Boeckh, F M. Marty, Villano	ATC 2017						~			
Poster	Study 203: Primary efficacy and safety data (encore of ID Week)	<u>Maertens J</u> , Cordonnier C, Jaksch P, Poire X, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S	BMT Tandem 2017					~				
Oral Presentation	Study 203: Pre-specified subgroup analyses by transplant type (SOT vs SCT)	<u>Maertens J</u> , Cordonnier C, Jaksch P, Poire X, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S	EBMT 2017					~				

Maribavir Phase 2 Studies Data Presentation

Type of Presentation		Authors	2016				2017				
	Description	Presenting Author	Congress	1	2	3	4	1	2	3	4
Oral Posters	Study 202: Primary efficacy and safety Study 203: Primary efficacy and safety	Papanicolaou G, Silveira F, Langston A, Pereira M, Avery R, Wijatyk A, Wu J, Boeckh M, Marty F, Villano S Maertens J, Cordonnier C, Jaksch P, Poire X, Wu J, Wijatyk A, <u>Saliba F</u> , Witzke O, Villano S	ID Week 2016				~				
Oral Presentation	Study 202: Primary efficacy and safety data, and pre- specified subgroup analyses by transplant type (SOT vs SCT)	<u>Papanicolaou G</u> , Silveira F, Langston A, Pereira M, Avery R, Wijatyk A, Wu J, Boeckh M, Marty F, Villano S	BMT Tandem 2017					✓			
Oral Plenary Presentation	Study 202: Primary efficacy and safety data, and pre- specified subgroup analyses by transplant type (SOT vs SCT)	<u>M R. Pereira</u> , F P. Silveira,G Papanicolaou, A Langston, R Avery, A Wijatyk,J J. Wu, M Boeckh, F M. Marty, Villano	ATC 2017						✓		
Poster	Study 203: Primary efficacy and safety data (encore of ID Week)	<u>Maertens J</u> , Cordonnier C, Jaksch P, Poire X, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S	BMT Tandem 2017					✓			
Oral Presentation	Study 203: Pre-specified subgroup analyses by transplant type (SOT vs SCT)	<u>Maertens J</u> , Cordonnier C, Jaksch P, Poire X, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S	EBMT 2017					✓			

SHP620-302: Phase 3 Pre-emptive Maribavir for CMV Viremia in Stem Cell Transplant Recipients




Primary	Confirmed clearance of plasma CMV DNA (CMV viremia clearance) at the end of 8 weeks of treatment
Endpoint	• Key Secondary - Maintenance of CMV viremia clearance achieved after the end of 8 weeks of treatment
	through Study Week 16

Current	Target 550 patients enrolled at sites in North America, Latin America, Europe, and Asia Pacific
Status	Open in North America & Europe and actively recruiting subjects
	 Web link to see active sites: www.shiretrials.com/transplant



SHP620-303: Phase 3 Open-Label Maribavir Compared with Investigator-Assigned Treatment of Resistant/Refractory CMV Infection in Transplant Recipients



Primary Endpoint		 Confirmed clearance of plasma CMV DNA (CMV viremia clearance) at the end of 8 weeks of treatment Key secondary - CMV viremia clearance at the end of 8 weeks of treatment and resolution/improvement of tissue invasive CMV disease for subjects symptomatic at baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease for subjects asymptomatic at baseline at the end of 8 weeks of treatment, followed by maintenance of this treatment effect for an additional 8 weeks off
		treatment
	Current	 Target 351 subjects enrolled at sites in North America, Europe, and Asia Pacific
	Status	 Open and actively recruiting subjects at sites in all regions

• Web link to see active sites: www.shiretrials.com/transplant

